Eli Lilly said Monday it will buy Loxo Oncology for $8 billion ... For MasterCard, not enough to keep it in the logo. The company is removing the word MasterCard from the pair of interlocking ...

STAMFORD, Conn., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the development and commercialization of highly selective medicines for ...

FILE PHOTO: The logo of Swiss drugmaker Roche is seen at ... as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area. The trial results on ...

STAMFORD, Conn., June 03, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with ...

STAMFORD — Loxo Oncology — whose first cancer medicine was recently approved by the U.S. Food & Drug Administration — will be sold for about $8 billion to pharmaceutical giant Eli Lilly & Co ...

Here are the key details of the proposed takeover offer: Lilly has agreed to commence a tender offer to acquire all outstanding shares of Loxo Oncology for approximately $8 billion. That ...

Loxo Oncology Inc. LOXO stock was up as much as 15.6% in Monday morning trade after announcing positive phase 1 trial results for its cancer drug LOXO-101. The company said the drug showed results ...

Loxo Oncology, a biotech developing small molecule therapeutics to treat solid tumors, announced terms for its IPO on Monday. The Stamford, CT-based company plans to raise $57 million by offering ...

It's been a year since Loxo Oncology sold itself to Eli Lilly for $8 billion, after a whirlwind 18-day sale process. And in an unusual turn, Loxo CEO Josh Bilenker is still with the company.

Eli Lilly and Co. announced Monday it will acquire Loxo Oncology for about $8 billion in cash. The move signals a major push into the cancer drug industry for the global pharmaceutical company ...